Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

April 22, 2022 Climate Change and Lung Cancer With Joan Schiller and Eric Bernicker
On a special Earth Day episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by two vocal IASLC members who have taken a passionate interest in understanding more about the climate crisis and how it impacts our patients with lung cancer.
49 min
April 19, 2022 Lung Cancer Considered 100th Episode - Interview with new IASLC CEO, Dr. Karen Kelly
In the 100th episode of IASLC's Lung Cancer Considered, host Dr. Narjust Duma interviews new IASLC CEO, Dr. Karen Kelly. Dr. Kelly is recognized internationally for her expertise in lung cancer research and her career has been dedicated to providing enhanced cancer care through innovative and groundbreaking clinical trials. Dr. Kelly’s lung cancer research has involved all aspects of the disease from risk reduction to screening to treatment. She has been at the forefront of drug development to treat lung cancer for decades. Dr. Kelly is the first female to hold this post in the association’s almost 50-year history.
39 min
April 05, 2022 ELCC 2022 Highlights With Nicolas Girard And Lizza Hendriks
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently completed European Lung Cancer Congress. His guests include Dr. Lizza Hendriks, assistant professor at Maastricht University in the Netherlands. Dr. Hendriks is also a pulmonologist specializing in thoracic oncology and the program leader of the Innovative Cancer Diagnostics Therapy group at GROW School of Oncology. Joining Dr. Hendriks is Dr. Nicolas Girarda, professor of Respiratory Medicine at the Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute in Paris.
27 min
March 15, 2022 Breakthrough Therapies NTRK With Robert Doebele
In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics about NTKR gene fusions, including recent and emerging breakthrough therapies.
33 min
March 01, 2022 Targeted Therapies of Lung Cancer with Charu Aggarwal Lecia Sequist and Ivy Elkins
The IASLC Targeted Therapies Meeting has historically been a very interactive, fast-paced meeting that highlights the latest and most innovative anticancer drugs, initially focused on targeted agents but in recent years, extending to immunotherapy.
In this Lung Cancer Considered podcast hosts Dr. Narjust Duma and Dr. Stephen Liu lead a wide-ranging discussion of the meeting with three lung cancer experts who attended the meeting:
Dr. Lecia Sequist is a thoracic medical oncologist at Massachusetts General Hospital, the Landry Family Professor of Medicine at Harvard Medical School, the Director of the Center for Innovation in Early Cancer Detection and a board member of the IASLC.
Ivy Elkins was diagnosed with Stage IV lung cancer in Dec 2013 as a healthy 47-year-old, Ivy was found to have an EGFR mutation and has spent the years since her diagnosis educating herself and advocating for herself and those within the lung cancer community. Ivy is a patient advocate and co-founder of the EGFR Resisters Lung Cancer Patient Group.
Dr. Charu Aggarwal is a thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania.
49 min
February 22, 2022 NTRK with Herbert Ho Fung Loong
Neurotrophic tyrosine receptor kinase fusion, or NTRK, has emerged in the last six years as a rare, but targetable alteration in several cancers. Dr. Herbert Loong, clinical assistant professor in the department of clinical oncology and deputy medical director of the Phase 1 Clinical Trials Center of The Chinese University of Hong Kong, joins Lung Cancer Considered host Dr. Stephen Liu to discuss NTRK and what impact it may have on lung cancer research and treatment.
27 min
February 15, 2022 ALK-Fusion Positive NSCLC With Jessica Jiyeong Lin And Ben Solomon
Lung Cancer Considered hosts Dr. Narjust Duma and Dr. Stephen Liu discuss ALK-fusion positive NSCLC with Dr. Jessica Lin, a physician at the Massachusetts General Hospital Cancer Center and an Assistant Professor of Medicine at Harvard Medical School, and Dr. Ben Solomon, a professor and consultant medical oncologist at Peter MacCallum Cancer Center in Melbourne, Australia.
46 min
February 01, 2022 Breakthrough Therapies EGFR Mutant Lung Cancer with Zosia Piotrowska
In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks with Dr. Zosia Piotrowska, Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital in Boston, Mass., about the current and future state of therapies for patients with EGFR mutant lung cancer.
32 min
January 18, 2022 Cell Therapy With Ben Creelan And Prasad Adusumilli
Cell therapy has made strides in hematology and oncology and has recently shown promise in thoracic oncology. In this episode of Lung Cancer Considered host, Dr. Narjust Duma delves into this emerging therapy with guests Dr. Ben Creelan, associate professor of medicine at the University of South Florida, thoracic oncologist at Moffitt Cancer Center and Dr. Prasad Adusumilli, deputy chief and attending of the thoracic service, vice chair for translational research in the department of surgery at Memorial Sloan Kettering Cancer Center.
38 min
January 04, 2022 Virtual Tumor Board EGFR With Helena Yu And Alfredo Addeo
This episode of Lung Cancer Considered focuses on an EGFR mutant non-small cell lung cancer virtual tumor board case that involves a 41-year-old woman who is a never smoker and presents with a dry cough, chest pain, and weight loss. Discussing treatment options on this podcast with host Dr. Narjust Duma are Dr. Alfredo Addeo, senior oncologist at Geneva Hospital in Geneva, Switzerland, and Dr. Helena Yu, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City.
45 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.